Seqens Seqens

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Mitotech","sponsor":"Essex Bio","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mitotech and Essex Bio-Technology Complete Enrollment in VISTA-2 \u2013 a pivotal Phase 3 Clinical Study of SkQ1 for Dry Eye Disease","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"LUXEMBOURG","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III"},{"orgOrder":0,"company":"Mitotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mitotech Granted Orphan Drug Designation by FDA for Visomitin in LHON","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"LUXEMBOURG","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2021","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III"},{"orgOrder":0,"company":"Mitotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mitotech CSO to Present at Mitochondria-Targeted Drug Development Summit","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"LUXEMBOURG","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2022","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III"}]

    Find Clinical Drug Pipeline Developments & Deals by Mitotech

    Menu

    Mitotech

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Mitotech

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Luxembourg
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Mitotech CSO to Present at Mitochondria-Targeted Drug Development Summit

              Details:

              SkQ1 (visomitin), is a cardiolipin peroxidation inhibitor, designed to sustain and restore mitochondrial function and interrupt apoptosis in mitochondrial conditions like LHON, dry eye disease and glaucoma.

              Lead Product(s): Visomitin

              Therapeutic Area: Ophthalmology Product Name: SkQ1

              Highest Development Status: Phase III Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable February 24, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Mitotech

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Luxembourg
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Mitotech Granted Orphan Drug Designation by FDA for Visomitin in LHON

              Details:

              USFDA has granted ODD for the company’s topical cardiolipin peroxidation inhibitor, SkQ1(Visomitin), for the treatment of Leber’s Hereditary Optic Neuropathy a rare inherited condition that can lead to blindness.

              Lead Product(s): Visomitin

              Therapeutic Area: Ophthalmology Product Name: SkQ1

              Highest Development Status: Phase III Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable December 15, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Mitotech

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Luxembourg
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Mitotech and Essex Bio-Technology Complete Enrollment in VISTA-2 – a pivotal Phase 3 Clinical Study of SkQ1 for Dry Eye Disease

              Details:

              VISTA-2 is a multi-centre, randomized, double-blind, placebo-controlled clinical study involving two treatment arms: SkQ1 ophthalmic solution and vehicle solution, administered BID.

              Lead Product(s): Visomitin

              Therapeutic Area: Ophthalmology Product Name: SkQ1

              Highest Development Status: Phase III Product Type: Small molecule

              Partner/Sponsor/Collaborator: Essex Bio

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable August 25, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.
              ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.
              Post Enquiry
              POST ENQUIRY